Skip to content
Esophageal Cancer Action Network Logo
  • ABOUT US
    • OUR STORY
    • FINANCIAL REPORTING
    • BOARD OF DIRECTORS
  • FACTS
    • Understanding Esophageal Cancer
    • Detecting and Diagnosing Esophageal Cancer
      • Expert Interview
    • Treating and Managing Esophageal Cancer
    • ESOPHAGEAL CANCER NEWS
    • ECAN WEBINARS
      • Inherited Gene Mutations and the link to Esophageal Adenocarcinoma
      • The Latest in Esophageal Cancer Treatment Options
      • Zolbetuximab (Vyloy) for Advanced GE Junction Adenocarcinoma
      • ctDNA and Esophageal Cancer
      • Missing the Diagnosis of Esophageal Cancer
    • THE LATEST MEDICAL RESEARCH
    • DOWNLOAD THE PATIENT GUIDE
    • MORE INFORMATION
  • FOR PATIENTS
    • IF YOU’VE BEEN DIAGNOSED
    • A COMMUNITY FOR SUPPORT
    • Intelligent Nutrition Assistant: Ina®
    • CLINICAL TRIALS PORTAL
      • CLINICAL TRIALS MATCHING SERVICE
  • GET INVOLVED
    • April is Esophageal Cancer Awareness Month!
    • ADVOCATE
      • ESOPHAGEAL CANCER RESEARCH FUNDING
    • JOIN OUR COMMUNITY!
    • JOIN STACY’S ARMY!
    • EVENTS
      • 2025 Steps to Save Lives Virtual 5K
      • PAINT YOUR TOWN PERIWINKLE – DIY EVENTS
    • Share Your EC Story
      • Your Stories
  • BUY PERIWINKLE
  • TRIBUTES
    • MEMORIAL TRIBUTES
    • IN APPRECIATION WE HONOR
    • MAKE AN HONOR OR TRIBUTE GIFT
  • CONTACT
  • GIVE NOW
    • Join Fight Club

New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma

The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic  HER2+ [...]

New Treatment Option for Patients with HER2+ Gastroesophageal Junction AdenocarcinomaMindy Mintz Mordecai2021-01-21T22:14:22+00:00

Latest US Stats Show More Esophageal Cancer Cases, Fewer Deaths

The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]

Latest US Stats Show More Esophageal Cancer Cases, Fewer DeathsMindy Mintz Mordecai2021-01-21T21:31:57+00:00

Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant Benefits

Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]

Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant BenefitsMindy Mintz Mordecai2020-09-22T00:51:54+00:00

Personalized Approach Shows Survival Benefit in Esophageal Adenocarcinoma

Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]

Personalized Approach Shows Survival Benefit in Esophageal AdenocarcinomaMindy Mintz Mordecai2020-09-22T01:15:19+00:00

Immunotherapy Breakthroughs for Esophageal Cancer Patients

The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]

Immunotherapy Breakthroughs for Esophageal Cancer PatientsMindy Mintz Mordecai2020-09-22T00:53:07+00:00

Barrett’s Esophagus and Esophageal Adenocarcinoma can run in Families

The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]

Barrett’s Esophagus and Esophageal Adenocarcinoma can run in FamiliesMindy Mintz Mordecai2020-08-14T00:07:02+00:00

FDA calls New Screening Test Using DNA to Detect Esophageal Cancer a Breakthrough Device

First Time the FDA has given Breakthrough Designation for a Device Targeting Diseases of the Esophagus. Lucid Diagnostics' EsoGuard™ Esophageal [...]

FDA calls New Screening Test Using DNA to Detect Esophageal Cancer a Breakthrough DeviceMindy Mintz Mordecai2020-08-14T00:39:25+00:00

FDA Approves First Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma

The U.S. Food and Drug Administration has approved Keytruda (Pembrolizumab) for treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC).  It [...]

FDA Approves First Immunotherapy for Advanced Esophageal Squamous Cell CarcinomaMindy Mintz Mordecai2019-08-15T23:40:13+00:00

First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer

First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in [...]

First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Canceradmin2024-02-08T07:04:56+00:00

$26 Million ‘Grand Challenge’ Project Will Probe Role of Inflammation in Cancer

Unprecedented International Collaboration will Focus on Esophageal and other Cancers with $26 Million UK Grant.  Read more about this [...]

$26 Million ‘Grand Challenge’ Project Will Probe Role of Inflammation in Canceradmin2019-01-27T14:12:56+00:00
Previous234Next

 

P.O. Box 243, Stevenson, Maryland 21153

410-358-3226 | info@ecan.org

Privacy Policy

The Internal Revenue Service has designated ECAN Esophageal Cancer Action Network a 501 (c)(3) charity. Donations to ECAN are tax deductible to the full extent of the law.
All content ©2024 by ECAN. All Rights Reserved. Website by New Frame Creative.
Give Now